| These Analysts Lower Their Forecasts On Zimmer Biomet After Q1 Results |
Zimmer Biomet Holdings, Inc ZBH reported better-than-expected earnings for the first quarter on Monday. |
benzinga.com |
2025-05-06 18:22:26 |
Czytaj oryginał (ang.) |
| S&P 500 INDEX (SPX) Live: The Markets Turn Cautious in Data-Filled Week |
Live Updates Live Coverage Has Ended Markets Pivot to Ford Earnings 4:03 pm by Gerelyn Terzo The markets failed to turn around, ending the trading session lower across the board and ending a multi-session winning streak. Stocks are awaiting further details on trade deals, which the White House has revealed could come as soon as this week, which would not be soon enough for the markets. Ford (NYSE: F) stock fell just over 1% on the day ahead of the automaker’s quarterly results after the closing bell today. When fellow automaker General Motors (NYSE: GM) reported its quarterly results last month, the company withdrew its profit guidance due to tariff uncertainty. Here’s how the major indices finished the trading day: Dow Jones Industrial Average: Down 69.52 (-0.17%) Nasdaq Composite: Down 132.40 (-0.74%) S&P 500: Down 36.79 (-0.66%) Economic Uncertainty 12:32 pm by Gerelyn Terzo U.S. Treasury Secretary Scott Bessent is making the rounds, speaking to global investors today about President Trump’s economic plan. He pointed to a three-pronged approach, including tariffs, tax cuts and deregulation. Bessent’s remarks failed to provide any greater clarity on the status of tariff negotiations with key U.S. trade partners, leaving the markets at a standstill. The three major stock market averages remain mixed, with the Dow Jones Industrial Average moving higher while the S&P 500 and Nasdaq Composite remain lower. Winners and Losers 10:43 am by Gerelyn Terzo Airline stock Delta (NYSE: DAL) is gaining 3% on the day, while United Airlines (Nasdaq: UAL) is tacking on 2.7%. EQT (NYSE: EQT) is advancing by 2.9% on the day on the heels of a dividend announcement. Ralph Lauren (NYSE: RL) is up 2.8%. Tyson Foods (NYSE: TSN) is losing 9.6% today on a quarterly revenue miss. Zimmer Biomet (NYSE: ZBH) is also down 9%. In what is proving to be a volatile session on Wall Street, the markets have come off their lows of the session. The markets are coming off the heels of a nine-day winning streak and have come out of the gate with plenty of headlines to process, chief among which has been the announced retirement of Berkshire Hathaway (NYSE: BRK-B) CEO Warren Buffett. Wall Street firm TD Cowen has issued a report suggesting that price increases from tariffs will be reflected in May’s inflation data. The Federal Reserve gathers this week to determine the near-term outlook on interest rates while the markets will also be paying close attention to the tone in comments from Chairman Jerome Powell. First-quarter earnings continues to unfold as names like Palantir Technologies (Nasdaq: PLTR), Ford Motor (NYSE: F) and Diamondback Energy (Nasdaq: FANG) take the spotlight. Mag Seven stocks are a mixed bag as shares of Apple (Nasdaq: AAPL) extend their losses with a 2% decline today. Sectors of the economy were originally all lower but industrials and telecom stocks have since made their way into the green. Netflix (Nasdaq: NFLX) shares are lower after President Trump tossed in fresh tariffs on foreign-made films. Here’s a look at the performance as of morning trading: Dow Jones Industrial Average: Down 50.53 (-0.12%) Nasdaq Composite: Down 133.34 (-0.74%) S&P 500: Down 32.82 (-0.58%) Market Movers Berkshire Hathaway (NYSE: BRK-B) is down 6% but maintains a $1.1 trillion market cap as Buffett prepares to pass the reins to his successor Greg Abel at the end of the year. Footwear stock Skechers (NYSE: SKX) has decided to leave the publicly traded markets behind and has accepted a private equity takeover by 3G Capital for $63 per share, sending the stock higher by 25% percentage today. Jefferies maintains a “hold” rating on Tesla (Nasdaq: TSLA), suggesting the valuation has already given the stock the benefit of the doubt in areas like tech innovation and scalability. Mizuho analysts are bullish on Bloom Energy (NYSE: BE), lifting shares to an “outperform” rating from “neutral” on an attractive risk/reward profile and sending the stock 3.5% higher today. The post S&P 500 INDEX (SPX) Live: The Markets Turn Cautious in Data-Filled Week appeared first on 24/7 Wall St.. |
https://247wallst.com |
2025-05-06 16:05:32 |
Czytaj oryginał (ang.) |
| Zimmer Biomet: Stronger Cash Flows Needed Before The Stock Rebounds |
Zimmer Biomet's stock dropped nearly 10% on the back of soft Q1 results. Despite structural tailwinds, Zimmer Biomet's business is struggling in the face of high interest rates, trade tensions and competition. Zimmer Biomet's cash flows appear set to be particularly hard hit by tariffs, meaning the company's share price is likely to remain depressed until this is resolved. |
seekingalpha.com |
2025-05-06 11:39:00 |
Czytaj oryginał (ang.) |
| Hip Implant Maker Zimmer Biomet Cuts Annual Profit Forecast On Paragon 28 Deal |
Zimmer Biomet Holdings, Inc ZBH reported first-quarter adjusted EPS of $1.81, down from $1.94 a year ago, beating the Street estimates of $1.77. |
benzinga.com |
2025-05-05 19:34:30 |
Czytaj oryginał (ang.) |
| ZBH Q1 Earnings Beat, Operating Margin Dips, Stock Down in Premarket |
Zimmer Biomet reports solid first-quarter performance across its geographic regions. However, contraction in its operating margin is a concern. |
zacks.com |
2025-05-05 18:00:35 |
Czytaj oryginał (ang.) |
| Zimmer Biomet Holdings, Inc. (ZBH) Q1 2025 Earnings Call Transcript |
Zimmer Biomet Holdings, Inc. (NYSE:ZBH ) Q1 2025 Earnings Conference Call May 5, 2025 8:30 AM ET Company Participants David DeMartino - SVP, IR Ivan Tornos - President & CEO Suketu Upadhyay - CFO & EVP, Finance, Operations & Supply Chain Conference Call Participants Robbie Marcus - JPMorgan David Roman - Goldman Sachs Chris Pasquale - Nephron Matthew O'Brien - Piper Sandler Matthew Taylor - Jefferies Larry Biegelsen - Wells Fargo Josh Jennings - TD Cowen Travis Steed - Bank of America Joanne Wuensch - Citi Caitlin Cronin - Canaccord Genuity Richard Newitter - Truist Securities Shagun Singh - RBC Rick Wise - Stifel Jeff Johnson - Baird Mike Matson - Needham & Company Operator Good morning, ladies and gentlemen, and welcome to the Zimmer Biomet First Quarter 2025 Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded today, May 5, 2025. |
seekingalpha.com |
2025-05-05 16:05:19 |
Czytaj oryginał (ang.) |
| Zimmer (ZBH) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates |
While the top- and bottom-line numbers for Zimmer (ZBH) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values. |
zacks.com |
2025-05-05 14:35:54 |
Czytaj oryginał (ang.) |
| Zimmer Biomet (ZBH) Surpasses Q1 Earnings and Revenue Estimates |
Zimmer Biomet (ZBH) came out with quarterly earnings of $1.81 per share, beating the Zacks Consensus Estimate of $1.76 per share. This compares to earnings of $1.94 per share a year ago. |
zacks.com |
2025-05-05 12:40:36 |
Czytaj oryginał (ang.) |
| Zimmer Biomet lowers 2025 profit forecast on acquisition costs, tariff uncertainty |
Zimmer Biomet Holdings on Monday lowered its full-year adjusted profit forecast, as the medical device maker anticipates a hit from its recent acquisition of Paragon 28 , currency volatility, and proposed tariffs. |
reuters.com |
2025-05-05 11:40:18 |
Czytaj oryginał (ang.) |
| Insights Into Zimmer (ZBH) Q1: Wall Street Projections for Key Metrics |
Get a deeper insight into the potential performance of Zimmer (ZBH) for the quarter ended March 2025 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics. |
zacks.com |
2025-04-30 14:21:06 |
Czytaj oryginał (ang.) |
| Zimmer Biomet to Report Q1 Earnings: Here's What to Expect |
ZBH's Hips business is expected to have witnessed growth on the back of its suite of navigation solutions in direct anterior stems and surgical impactors. |
zacks.com |
2025-04-22 13:15:33 |
Czytaj oryginał (ang.) |
| Zimmer Biomet Completes Acquisition of Paragon 28 |
Transaction Further Strengthens Company's Position in High-Growth Foot and Ankle Segment WARSAW, Ind., April 21, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. ("Zimmer Biomet"; NYSE and SIX: ZBH), a global medical technology leader, today announced it has completed the acquisition of Paragon 28, Inc. ("Paragon 28"), a leading medical device company focused exclusively on the fast-growing foot and ankle orthopedic space. |
prnewswire.com |
2025-04-21 13:00:00 |
Czytaj oryginał (ang.) |
| Zimmer Biomet Announces Webcast and Conference Call of First Quarter 2025 Financial Results |
WARSAW, Ind. , April 10, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today announced its first quarter earnings conference call will be webcast on Monday, May 5, 2025, at 8:30 a.m. |
prnewswire.com |
2025-04-10 11:30:00 |
Czytaj oryginał (ang.) |
| ZBH Stock to Gain From Volume Growth Amid Rising Costs |
Zimmer Biomet is strategically expanding its global presence to address the huge demand in the musculoskeletal space. |
zacks.com |
2025-04-07 17:15:30 |
Czytaj oryginał (ang.) |
| PARAGON 28 INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Paragon 28, Inc. - FNA |
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Paragon 28, Inc. (NYSE: FNA) to Zimmer Biomet Holdings, Inc. (NYSE: ZBH). Under the terms of the proposed transaction, shareholders of Paragon will receive $13.00 in cash as well as a non-tradeable contingent value right, entitling the holder to receive up to $1.00 per share in cash if certain revenue mileston. |
businesswire.com |
2025-04-02 16:47:00 |
Czytaj oryginał (ang.) |
| Zimmer Biomet Receives CE Mark Approval for RibFix Advantage® Fixation System |
Expanding Thoracic Portfolio WARSAW, Ind., and ZUG, Switzerland , April 1, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE: ZBH and SIX: ZBH), a global medical technology leader, today announced its RibFix Advantage® Fixation System has received CE Mark certification – the first CE Mark for an intrathoracic rib fixation system. |
prnewswire.com |
2025-04-01 11:30:00 |
Czytaj oryginał (ang.) |
| 3 Promising Surgical Robotics Stocks to Keep an Eye on in 2025 |
Investing in surgical robotics stocks like ISRG, ZBH and STXS can be profitable for investors in 2025. |
zacks.com |
2025-03-26 13:10:22 |
Czytaj oryginał (ang.) |
| Should You Consider Retaining ZBH Stock in Your Portfolio Now? |
Zimmer Biomet's robust Knee business appears promising. However, a dull macroeconomic condition adds to the worry. |
zacks.com |
2025-03-21 15:15:26 |
Czytaj oryginał (ang.) |
| Zimmer Biomet Focuses on Innovation Amid Growing Competition |
Among Zimmer Biomet's knee solutions featured at the AAOS 2025, the newly cleared Persona Revision SoluTion Femur is expected to draw attention. |
zacks.com |
2025-03-14 12:55:27 |
Czytaj oryginał (ang.) |
| ZBH Stock to Gain From Global Expansion Amid Difficult FX Scenario |
Zimmer Biomet is strategically expanding its global presence to address the huge demand in the musculoskeletal space. |
zacks.com |
2025-03-12 15:20:31 |
Czytaj oryginał (ang.) |
| Zimmer Biomet Launches You'll Be Back Campaign with Chief Movement Officer Arnold Schwarzenegger |
Schwarzenegger Invites People Living with Joint Pain to Join New Online Community, Share Their Stories and Connect with a Qualified Physician WARSAW, Ind. , Feb. 26, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced the launch of the You'll Be Back campaign with the Company's Chief Movement Officer, Arnold Schwarzenegger. |
prnewswire.com |
2025-02-26 09:30:00 |
Czytaj oryginał (ang.) |
| ZBH Stock Hurt by Margin Concerns and Difficult Solvency |
Zimmer Biomet is suffering due to macroeconomic uncertainties, pricing pressure and unfavorable currency fluctuations. |
zacks.com |
2025-02-17 13:56:10 |
Czytaj oryginał (ang.) |
| Zimmer Biomet: Adding To The Growth Profile |
Zimmer Biomet shares at $105 reveal value at 13 times adjusted earnings, as the company continues to grow despite a GLP-1 drug overhang. The 2015 Zimmer Biomet merger hasn't been fully delivered, but recent organic growth and M&A actions are promising, with mid-single digit sales growth projected. The $1.2 billion Paragon 28 acquisition enhances foot and ankle orthopedics, despite short-term EPS dilution, and boosts Zimmer Biomet's growth profile. |
seekingalpha.com |
2025-02-07 08:45:34 |
Czytaj oryginał (ang.) |
| ZBH's Q4 Earnings Beat, Margins Contract, Stock Down in Premarket |
Zimmer Biomet benefits from its diversified portfolio outside of core orthopedics and the company's strategic investments in attractive, higher-growth segments. |
zacks.com |
2025-02-06 15:41:12 |
Czytaj oryginał (ang.) |
| Why Is Zimmer Biomet Stock Trading Lower On Thursday? |
On Thursday, Zimmer Biomet Holdings, Inc ZBH reported fourth-quarter adjusted EPS of $2.31, up from $2.20 a year ago, beating the Street estimates of $2.30. |
benzinga.com |
2025-02-06 15:10:01 |
Czytaj oryginał (ang.) |
| Zimmer Biomet Holdings, Inc. (ZBH) Q4 2024 Earnings Call Transcript |
Zimmer Biomet Holdings, Inc. (NYSE:ZBH ) Q4 2024 Earnings Conference Call February 6, 2025 8:30 AM ET Company Participants David DeMartino - Senior Vice President-Investor Relations Ivan Tornos - President and Chief Executive Officer Suketu Upadhyay - CFO and EVP, Finance, Operations and Supply Chain Conference Call Participants Robbie Marcus - JPMorgan Patrick Wood - Morgan Stanley Steven Lichtman - Oppenheimer and Company Matt Taylor - Jefferies David Roman - Goldman Sachs Vik Chopra - Wells Fargo Ryan Zimmerman - BTIG Danielle Antalffy - UBS Travis Steed - Bank of America Rick Wise - Stifel Matt Miksic - Barclays Jayson Bedford - Raymond James Operator Good morning, ladies and gentlemen, and welcome to the Zimmer Biomet Fourth Quarter 2024 Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded today, February 06, 2025. |
seekingalpha.com |
2025-02-06 13:54:12 |
Czytaj oryginał (ang.) |
| Zimmer (ZBH) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates |
Although the revenue and EPS for Zimmer (ZBH) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers. |
zacks.com |
2025-02-06 12:36:56 |
Czytaj oryginał (ang.) |
| Zimmer Biomet forecasts 2025 profit below estimates |
Medical device maker Zimmer Biomet Holdings forecast full-year adjusted profit below Wall Street estimates on Thursday, as it anticipates a hit from a strong dollar. |
reuters.com |
2025-02-06 10:41:40 |
Czytaj oryginał (ang.) |
| Zimmer Biomet (ZBH) Surpasses Q4 Earnings and Revenue Estimates |
Zimmer Biomet (ZBH) came out with quarterly earnings of $2.31 per share, beating the Zacks Consensus Estimate of $2.30 per share. This compares to earnings of $2.20 per share a year ago. |
zacks.com |
2025-02-06 10:41:10 |
Czytaj oryginał (ang.) |
| Zimmer Biomet Announces Fourth Quarter and Full-Year 2024 Financial Results |
Fourth quarter net sales of $2.023 billion increased 4.3% and 4.9% on a constant currency1 basis Fourth quarter diluted earnings per share were $1.20; adjusted1 diluted earnings per share were $2.31 Full-year net sales of $7.679 billion increased 3.8% and 4.8% on a constant currency1 basis Full-year diluted earnings per share were $4.43; adjusted1 diluted earnings per share were $8.00 Company provides full-year 2025 financial guidance WARSAW, Ind. , Feb. 6, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today reported financial results for the quarter and year ended December 31, 2024. |
prnewswire.com |
2025-02-06 08:30:00 |
Czytaj oryginał (ang.) |
| Unveiling Zimmer (ZBH) Q4 Outlook: Wall Street Estimates for Key Metrics |
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Zimmer (ZBH), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended December 2024. |
zacks.com |
2025-02-04 12:20:35 |
Czytaj oryginał (ang.) |
| ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Paragon 28, Inc. |
NEW YORK , Jan. 31, 2025 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Paragon 28, Inc. (NYSE: FNA) and its board of directors concerning the proposed acquisition of the company by Zimmer Biomet Holdings, Inc. (NYSE: ZBH). Stockholders will receive $13.00 and a contingent value right for up to $1.00 for each share of Paragon 28 stock that they hold. |
prnewswire.com |
2025-01-31 18:25:00 |
Czytaj oryginał (ang.) |
| Zimmer Biomet Set to Report Q4 Earnings: What's in Store? |
ZBH's Hips business is expected to have witnessed growth banking on its suite of navigation solutions in direct anterior stems and surgical impactors. |
zacks.com |
2025-01-31 13:47:13 |
Czytaj oryginał (ang.) |
| PARAGON 28 INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Paragon 28, Inc. - FNA |
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Paragon 28, Inc. (NYSE: FNA) to Zimmer Biomet Holdings, Inc. (NYSE: ZBH). Under the terms of the proposed transaction, shareholders of Paragon will receive $13.00 in cash as well as a non-tradeable contingent value right, entitling the holder to receive up to $1.00 per share in cash if certain revenue mileston. |
businesswire.com |
2025-01-29 21:09:00 |
Czytaj oryginał (ang.) |
| Zimmer Biomet to buy Paragon 28 for $1.1 billion |
Zimmer Biomet said on Tuesday it would acquire medical device company Paragon 28 for about $1.1 billion. |
reuters.com |
2025-01-28 20:11:50 |
Czytaj oryginał (ang.) |
| Emerging Market Expansion Supports ZBH Stock Amid Macro Issues |
Zimmer Biomet is witnessing strong market share gains within reconstructive Knees and Hips in key geographies despite macroeconomic challenges. |
zacks.com |
2025-01-21 13:36:12 |
Czytaj oryginał (ang.) |
| Should You Consider Retaining ZBH Stock in Your Portfolio Now? |
Zimmer Biomet's robust efforts to expand the Knee business and a gradually stabilizing musculoskeletal market appear promising. |
zacks.com |
2025-01-14 09:33:37 |
Czytaj oryginał (ang.) |
| Zimmer Biomet: Back On Offense With Strong Cash Flow Outlook |
Zimmer Biomet Holdings (ZBH) is expanding its product portfolio and improving cash flow, positioning it for long-term profitability and financial health. ZBH is undervalued compared to peers, with significant growth potential driven by innovation, acquisitions, and operational efficiency improvements. The company's focus on high-growth markets and improving profitability metrics indicate a strong future outlook, despite past underperformance. |
seekingalpha.com |
2025-01-05 19:25:50 |
Czytaj oryginał (ang.) |
| ZBH Stock to Benefit From Global Expansion Despite Macro Issues |
Zimmer Biomet is witnessing strong market share gains within reconstructive Knees and Hips in key geographies despite macroeconomic challenges. |
zacks.com |
2024-12-26 13:32:11 |
Czytaj oryginał (ang.) |
| ZBH Stock Might Rise Following FDA Nod for OsseoFit |
Zimmer Biomet's OsseoFit Stemless Shoulder System gets FDA 510(k) approval. The company expects to launch the system in the first quarter of 2025. |
zacks.com |
2024-12-16 10:36:20 |
Czytaj oryginał (ang.) |
| 2 Robotic Surgery Stocks Challenging Intuitive Surgical's Lead |
Robotic surgery used to be fodder for science fiction movies. Not anymore. |
marketbeat.com |
2024-12-12 09:01:28 |
Czytaj oryginał (ang.) |
| Reasons to Retain ZBH Stock in Your Portfolio for Now |
Zimmer Biomet's robust efforts to expand market share and a gradually stabilizing musculoskeletal market appear promising. |
zacks.com |
2024-12-06 11:51:27 |
Czytaj oryginał (ang.) |
| ZBH Stock Might Rise Following FDA Nod for Knee Implant Component |
Zimmer Biomet's Persona SoluTion Porous Plasma Spray Femur gets FDA 510(k) approval. The company expects to launch the system in the first quarter of 2025. |
zacks.com |
2024-12-05 10:55:32 |
Czytaj oryginał (ang.) |
| Zimmer Biomet Receives FDA Clearance for Persona® SoluTion™ PPS® Femur |
A Total Knee Replacement Alternative for Patients with Metal and/or Bone Cement Sensitivities WARSAW, Ind., Dec. 4, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of Persona® SoluTion™ Porous Plasma Spray (PPS®) Femur, a total knee implant component offering an alternative for patients with sensitivities to bone cement and/or metal. |
prnewswire.com |
2024-12-04 09:30:00 |
Czytaj oryginał (ang.) |
| Why Is Zimmer (ZBH) Up 4.8% Since Last Earnings Report? |
Zimmer (ZBH) reported earnings 30 days ago. What's next for the stock? |
zacks.com |
2024-11-29 14:36:13 |
Czytaj oryginał (ang.) |
| ZBH Stock Gains From FDA Nod for Oxford Cementless Partial Knee |
Zimmer Biomet receives FDA nod for the Oxford Cementless Partial Knee. It is a PMA Supplement approval. |
zacks.com |
2024-11-26 12:35:26 |
Czytaj oryginał (ang.) |
| Zimmer Biomet Receives FDA Approval for Oxford® Cementless Partial Knee, Only Cementless Partial Knee Replacement Implant in the U.S. |
WARSAW, Ind., Nov. 25, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced U.S. Food and Drug Administration (FDA) Premarket Approval Application (PMA) Supplement approval for the Oxford® Cementless Partial Knee. |
prnewswire.com |
2024-11-25 18:05:00 |
Czytaj oryginał (ang.) |
| Zimmer Biomet to Present at Citi's 2024 Global Healthcare Conference |
WARSAW, Ind. , Nov. 21, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today announced that members of the Zimmer Biomet management team will participate in the Citi Global Healthcare Conference on December 5, 2024, with a fireside chat at 8:45 a.m. |
prnewswire.com |
2024-11-21 09:30:00 |
Czytaj oryginał (ang.) |
| ZBH Stock Gains From Receiving CE Mark for Persona Revision Knee System |
Zimmer Biomet gets CE Mark Certification for Persona Revision Knee System, followed by the successful introduction in the United States and other markets. |
zacks.com |
2024-11-20 10:21:09 |
Czytaj oryginał (ang.) |
| Zimmer Biomet Announces CE Mark Certification for Persona® Revision Knee System |
WARSAW, Ind., and ZURICH , Nov. 18, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE: ZBH and SIX: ZBH), a global medical technology leader, today received the CE Mark for its Persona® Revision Knee System. |
prnewswire.com |
2024-11-18 09:30:00 |
Czytaj oryginał (ang.) |
| ZBH Stock to Gain Support From Market Share Gains Amid Macro Issues |
Zimmer Biomet expects ROSA and Persona Cementless Knee to enhance its robotics and cementless market penetration to 50% to 60% range at a rapid pace. |
zacks.com |
2024-11-11 13:25:43 |
Czytaj oryginał (ang.) |
| Orthopedic Implant Maker Zimmer Biomet Reports Better-Than-Expected Q3 Earnings, Updates Annual Forecasts |
On Wednesday, Zimmer Biomet Holdings, Inc ZBH reported third-quarter adjusted EPS of $1.74, up from $1.65 a year ago, in line with the Street estimates. |
benzinga.com |
2024-10-30 14:04:34 |
Czytaj oryginał (ang.) |
| ZBH Stock Up Despite Q3 Earnings Miss, 2024 View Narrowed |
Zimmer Biomet delivers strong performance across segments and regions in the third quarter of 2024. |
zacks.com |
2024-10-30 13:56:11 |
Czytaj oryginał (ang.) |
| Zimmer Biomet Holdings, Inc. (ZBH) Q3 2024 Earnings Call Transcript |
Zimmer Biomet Holdings, Inc. (NYSE:ZBH ) Q3 2024 Earnings Conference Call October 30, 2024 8:30 AM ET Company Participants David DeMartino – Senior Vice President-Investor Relations Ivan Tornos – President and Chief Executive Officer Suketu Upadhyay – Chief Financial Officer and Executive Vice President-Finance, Operations and Supply Chain Conference Call Participants Travis Steed – Bank of America Vik Chopra – Wells Fargo David Roman – Goldman Sachs Allen Gong – JPMorgan Matthew O'Brien – Piper Sandler Chris Pasquale – Nephron Steve Lichtman – Oppenheimer Sophia Knopp – Evercore ISI Richard Newitter – Truist Securities Jeff Johnson – Baird Caitlin Cronin – Canaccord Mike Matson – Needham & Company Shagun Singh – RBC Capital Markets Operator Good morning, ladies and gentlemen, and welcome to the Zimmer Biomet Third Quarter 2024 Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded today, October 30, 2024. |
seekingalpha.com |
2024-10-30 12:58:01 |
Czytaj oryginał (ang.) |
| Zimmer (ZBH) Reports Q3 Earnings: What Key Metrics Have to Say |
Although the revenue and EPS for Zimmer (ZBH) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers. |
zacks.com |
2024-10-30 12:35:34 |
Czytaj oryginał (ang.) |
| Implant maker Zimmer Biomet lowers full-year profit forecast |
Hip implant maker Zimmer Biomet lowered its annual profit forecast on Wednesday following last month's disruptions to a software platform that was managing some of the company's operations. |
reuters.com |
2024-10-30 11:22:39 |
Czytaj oryginał (ang.) |
| Zimmer Biomet (ZBH) Misses Q3 Earnings Estimates |
Zimmer Biomet (ZBH) came out with quarterly earnings of $1.74 per share, missing the Zacks Consensus Estimate of $1.75 per share. This compares to earnings of $1.65 per share a year ago. |
zacks.com |
2024-10-30 10:41:10 |
Czytaj oryginał (ang.) |
| What to Expect From These 3 MedTech Stocks This Earnings Season |
Here is a sneak peek into how three MedTech companies, ZBH, BIO and TECH, are expected to fare in their upcoming quarterly results, slated to be released tomorrow. |
zacks.com |
2024-10-29 14:31:25 |
Czytaj oryginał (ang.) |